<DOC>
	<DOC>NCT02498860</DOC>
	<brief_summary>Two-Year Disease Free Survival Rate of Stage IB~IIIA adenocarcinoma after Adjuvant Chemotherapy with Pemetrexed and Cisplatin will be assessed. A total of 106 patients will be recruited for 12 months, and followed for two years, thus the duration of study will be 36 months.</brief_summary>
	<brief_title>Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung</brief_title>
	<detailed_description>Primary endpoint : 2 year disease free survival Secondary endpoints: Overall survival, Frequency and severity of adverse events</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Adenocarcinoma of Lung Postoperative pathologic stage IB~IIIA Complete surgical resection (R0 resection) N12: R0 resection with lobectomy and mediastinal lymph nodes dissection (MLND) N0: R0 resection with lobectomy with or without MLND Adjuvant treatment should start between 4 to 6 weeks after surgery ECOG performance status 01 Weight loss during last 3 months should be less than 10%. Normal hematologic, hepatic and renal function Neutrophil count &gt; 1500 /microliter, Platelet &gt; 100,000/microliter, Hemoglobin &gt; 9 g/dL Bilirubin &lt;=1.5 x upper limit normal, transaminase &lt; 2.5 x upper limit normal Serum Creatinine &lt;=1.5 mg/dL Women in child bearing age should consent using contraceptive measures, and must have negative pregnancy test. Other malignant neoplastic disease within 5 years. Neoadjuvant chemotherapy before surgery of lung cancer Patients who will be treated with postoperative radiation. Stage IIIB or IV lung cancer Severe infection, or cardiorespiratory, hematologic illness HIV positive cases Pregnancy or lactating women Autoimmune diseases or those who receiving immune suppressive treatment Symptomatic neuropathy &gt; CTCAE grade 1 Those who consented other clinical trials within 3 months Other significant medical conditions contraindicated to clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>lung</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>cisplatin</keyword>
	<keyword>surgery</keyword>
</DOC>